Physician profile

Michael Guzzardo

San Diego, CA

NPI 1124722046

$528.65

in general payments reported to CMS, 2019-2025

7 companies · $192 in 2025

The $192 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$528.65

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $121.84 2025 Krystexxa
Elevate Surgical Co $107.92 2024-2025
Smith+Nephew, INC. $102.20 2024 Collagenase Santyl
Stryker Corporation $90.31 2024 Ortholoc 2 Lapifuse
Treace Medical Concepts, INC. $56.37 2025
Mimedx Group, INC. $29.06 2024
Acumed LLC $20.95 2024 Acumed

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Guzzardo

$528.65

in general payments reported 2019-2025

Years
2024-2025
Top company
Amgen INC.
Context
The $192 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/11692483/michael-guzzardo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.